HOUSTON, Dec. 11 U.S. scientists have found chronic lymphocytic leukemia patients treated with therapy that includes the drug oblimersen survive longer than other patients.
The University of Texas M.D. Anderson Cancer Center researchers said patients who achieved a complete response with oblimersen have survived so well that a median survival time cannot yet be calculated, but it's estimated to exceed 49 months. Those who achieved complete response with chemotherapy alone had a median survival time of 35 months.
"In a relapsed population, that's excellent survival," said lead study author Dr. Susan O'Brien.
The research was reported Monday in Atlanta during the 49th annual meeting of the American Society of Hematology.
Copyright 2007 by UPI
